Impact of Comorbidities, Some Biomarkers, Micro RNA in Childhood Asthma Phenotypes
ConditionBronchial Asthma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-12
SponsorAssiut University
About this trial
* Assess response to treatment in children with bronchial asthma attending Assiut university children hospital. * Role of comorbidities in controlling symptoms of bronchial asthma. * Evaluate the role of the soluable interleukin 5 receptor, I C-telopeptide of type I collagen (ICTP), miR-223-3p and miR-191-5p in bronchial asthma.
Eligibility criteria
Qualifiers
Children aged 6-12 years diagnosed asthma, inpatient or attending pediatric outpatient clinic of Assiut university children hospital.
Disqualifiers
- Chronic respiratory illness other than asthma (e.g., bronchiectasis, CF)
Known immunodeficiency or systemic illness
patients with skeletal deformities
patients suspected inborn errors of metabolism
Trial design
Treatments tested in this trial
- Short Acting Beta 2 Agonist
Treatment groups
82 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov